Fort Worth, Texas
2016 RANK: 11
Fiscal year ending: Dec. 31, 2016
R&D Spend: $486,000,000
Mike Ball, CEO; Kim Adler, head, global communications; Laurent Attias, head, strategy, BD&L & market access; Royce Bedward, SVP & general counsel; Ian Bell, president, EMEA; Sergio Duplan, president, North America; David Endicott, COO; Camila Finzi, president, Latin America & the Caribbean; Franck Leveiller, head, global R&D; Merrick McCracken, SVP, HR; Ed McGough, SVP, global manufacturing & technical operations; Jim Murphy, president, Japan; David Murray, CFO; Rajkumar Narayanan, president, Asia; Michael Onuscheck, head, Alcon Surgical; Dave Schoening, SVP quality; Eric van Oppens, head, global strategic initiatives
Alcon’s surgical and vision care businesses together boast one of the world’s widest selections of eye care devices. Products range from sophisticated eye surgery equipment to advanced contact lenses. Alcon went through a transition year in 2016, according to the annual report of Alcon’s parent company Novartis. There was more of a concentration on eye care devices – as well as R&D investment and new systems and capabilities to boost relationships with customers. Rumors once again swirled last year about a possible private equity spinout or IPO for Alcon; with CEO Joe Jimenez turning the corner office over to Dr. Vasant Narasimhan early next year, those rumors are not likely to go away.
* Revenues from Novartis’ Alcon segment.